{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Other
Class (Stereo):
CHEMICAL (RACEMIC)
Conditions:
PD123319 is a potent, selective AT2 angiotensin II receptor antagonist with IC50 of 34 nM.PD123319 had been in phase I clinical trials by Pfizer for the treatment of hypertension. However, this research has been discontinued.
![Structure of {p-[(S)-2-[(S)-2-[5-(2,5-Dioxo-1-pyrrolidinyl)pentylcarbonylamino]-3-methylbutyrylamino]-5-ureidovalerylamino]phenyl}methyl formylate](/img/87917f08-af7b-491a-8acb-200668335055.svg?size=200&context=vrpmitlced)
![Structure of N-[4-(3,4-Dichlorophenyl)-3,4-dihydro-1(2H)-naphthalenylidene]methanamine](/img/e4ca07fb-42e1-471a-ad66-7f95df57d5aa.svg?size=200&context=vrpmitlced)
![Structure of 2,5-Anhydro-1,3,4-trideoxy-2-C-(2,4-difluorophenyl)-4-[[4-[4-[4-[(phenoxycarbonyl)amino]phenyl]-1-piperazinyl]phenoxy]methyl]-1-(1H-1,2,4-triazol-1-yl)-D-threo-pentitol](/img/330e926c-0932-45e8-bf89-1421903e3b1d.svg?size=200&context=vrpmitlced)
![Structure of 3-[(Acetyloxy)methylene]-1,3-dihydro-4-(4-methyl-1-piperazinyl)-2H-1,5-benzodiazepine-2-thione, (3Z)-](/img/98115d1f-391c-465b-a777-095c2b95c3f4.svg?size=200&context=vrpmitlced)
